{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:16:42Z","timestamp":1770977802090,"version":"3.50.1"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0214884","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T17:33:29Z","timestamp":1554226409000},"page":"e0214884","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-8334","authenticated-orcid":true,"given":"Francesca","family":"Consoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ausilia Maria","family":"Manganoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Incardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Vermi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giacomo","family":"Calzavara Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"GV Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/ K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"GV Long","year":"2017","journal-title":"Annals Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"GV Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"D Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"ref5","first-page":"667","article-title":"Long-Term Outcomes in Patients With BRAF V600\u2013Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib JCO","volume":"36","author":"GV Long","year":"2018","journal-title":"Long-Term Outcomes in Patients With BRAF V600\u2013Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib JCO"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous Complications of Targeted Melanoma Therapy","volume":"17","author":"E De Golian","year":"2016","journal-title":"Curr. Treat. Options in Oncol"},{"key":"ref7","first-page":"1797","article-title":"Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature","volume":"29","author":"R Mossner","year":"2015","journal-title":"JEADV"},{"issue":"1","key":"ref8","first-page":"115","article-title":"Vitiligo in Metastatic Melanoma Patients?","volume":"33","author":"R Ruiz-Villaverde","year":"2016","journal-title":"Can Vemurafenib Induce"},{"issue":"6","key":"ref9","first-page":"766","article-title":"Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma","volume":"15","author":"MR Nasca","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"ref10","first-page":"210","article-title":"Melanoma of unknown primary with nodal metastases, presenting with vitiligo-like depigmentation","volume":"147","author":"AM Manganoni","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"NA Galliker","year":"2015","journal-title":"Eur J Dermatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2018.06.030","article-title":"Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma","volume":"101","author":"G Ben-Betzalel","year":"2018","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"DT Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"ref14","first-page":"1111O","article-title":"Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone","volume":"27","author":"Y Yan","year":"2016","journal-title":"Annals of Oncology"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled prognostic subgroups for survival and treatment outcome in BRAF V600-mutated metastatic melanoma pooled analysis of 4 randomized clinical trials","volume":"4","author":"A Hauschild","year":"2018","journal-title":"Jama Oncol"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","article-title":"Immunological effects of BRAF + MEK inhibition","volume":"7","author":"PA Ascierto","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2017.00248","article-title":"Metabolic hallmarks of tumor and immune cell in the tumor microenvironment","volume":"8","author":"K Renner","year":"2017","journal-title":"Front Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0214884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T10:35:35Z","timestamp":1607164535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0214884"}},"subtitle":[],"editor":[{"given":"Roger","family":"Chammas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0214884","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}